German firms raise China investment by a third as US outlays slump - IW says

German companies increased investment in China by €5.6 billion ($6.5 billion) year over year in H1 2026, roughly one-third higher than a year earlier, while investment in the U.S. fell nearly two-thirds to about €4.3 billion amid tariff-driven trade tensions. The shift underscores China’s continued importance as both a sales market and low-cost production base for German industry, aided by subsidies and a weak yuan. The German Economic Institute warned that the trend could shift production and jobs from Germany, adding pressure for EU countervailing tariffs on Chinese imports.

Analysis

For BASF, incremental China localization is not automatically earnings-accretive: it protects customer access and reduces tariff/freight friction, but also increases exposure to the region’s structurally weak chemical pricing and subsidized local competitors. The key swing factor is whether localized output displaces higher-cost European production faster than it cannibalizes exports; the former supports group utilization and fixed-cost absorption, while the latter entrenches lower returns on capital. BASF’s China footprint therefore deserves a lower multiple unless management can demonstrate that local EBIT margins converge with, rather than remain below, legacy segment returns.

The second-order pressure falls on Germany-heavy chemical peers with less local scale—WCH and LXS are more exposed to European energy, labor and compliance costs without the same ability to serve Asian customers from inside China. Over 6-18 months, further capital migration risks weakening European utilization rates, which would prolong pricing pressure across basic chemicals and intermediates even if European gas costs ease. Conversely, industrial automation and process-equipment suppliers with meaningful China sales could benefit from localized plant investment, though this depends on domestic-content requirements and technology-transfer constraints.

Near-term, this is not a clean directional BAS catalyst because the investment data do not establish incremental BASF capex, volumes, or returns. The tradable confirmation would be a positive revision to BASF’s Asia-Pacific volume outlook and segment margin guidance alongside evidence of European capacity rationalization; absent both, the market is likely to treat additional China exposure as defensive rather than value-creating. Falsification of the bearish European-chemicals thesis would be a sustained recovery in European chemical utilization and pricing spreads, or material tariff protection that permits local producers to recapture margin.

Key Decisions for Investors

• Maintain a cautious/neutral stance on BAS over the next 1-3 months; do not add solely on the localization narrative. Upgrade only if quarterly disclosure shows Asia-Pacific volume growth translating into higher Chemicals/Materials EBIT margins and no offsetting deterioration in European utilization.
• Monitor a relative-value short basket of European, Germany-cost-base chemicals (WCH, LXS) versus BAS for a 3-6 month horizon if European order indicators and chemical price indices remain weak. The thesis is weaker local-market access and greater fixed-cost deleveraging; stop out if European utilization/pricing improves materially for two consecutive monthly reads.
• For existing BAS longs, use the next earnings release as the decision point: reduce if management raises China capital commitments without a quantified return, ramp-up timetable, or European capacity reduction. The principal downside is multiple compression from higher China concentration combined with still-subscale returns on invested capital.
• Set an alert for EU countervailing-duty action affecting Chinese chemical imports. A credible policy move would be a near-term positive catalyst for BAS, WCH and LXS through improved European pricing power, but could also invite retaliation against German industrial exports and should not be treated as unambiguously bullish.